The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

The test, which Santa Maria, California-based Hardy distributes in the US under a license from NG Biotech, is designed to detect CTX-M enzymes.

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

The company reported difficulties ahead for its immunodiagnostics business in China in the wake of changes in late April related to the country's Diagnosis-Related Groups (DRG) policy on hospital lab ...

Last week, readers were most interested in a story about Roche's blood-based Alzheimer's test getting CE marking.

The deal brings together Promega's Maxwell automated nucleic acid extraction system and Longhorn's viral molecular transport media.

The company raised its full-year revenue guidance slightly due to changing foreign exchange rates but lowered its full-year EPS guidance.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.